James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

5 Gene Therapy Stocks to Consider

Gene therapy is back, and this time looks like it's worth the effort. Five names stand out among the whole lot.

Why Southwest Airlines Co. (NYSE:LUV), Hudson City Bancorp, Inc. (NASDAQ:HCBK) and Gannett Co., Inc. (NYSE:GCI) Are 3 of Today’s Worst Stocks

Southwest Airlines (LUV), Hudson City Bancorp (HCBK) and Gannett Co. (GCI) skipped Monday's rally and instead found reasons to move much lower.

Rite Aid Earnings Preview: A Setup for a Pullback from RAD Stock?

Wednesday morning's Rite Aid earnings report for Q4 could end up sinking RAD shares ... even if the news is good.

Why Motorola Solutions Inc. (MSI), NuVasive, Inc. (NUVA) and Valero Energy Corporation (VLO) Are 3 of Today’s Worst Stocks

Motorola Solutions (MSI), NuVasive (NUVA) and Valero Energy (VLO) were the worst of the worst on Thursday. Here's why.

Apple Watch Sales Forecasts Already Bode Well for AAPL

It may not be the sole reason an investor would want to own AAPL stock, but the Apple watch certainly doesn't hurt.